National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024
33Dispensed price if dose is supplied by approved private hospital authority
Start here
Get a plain-English read of 33
Turn the raw legal text into a practical explanation grounded in National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024.
33 Dispensed price if dose is supplied by approved private hospital authority
(1) For a dose of a chemotherapy drug supplied by an approved hospital authority of a private hospital, the dispensed price is the sum of the following amounts: (a) the base price for the dose worked out under subsection (2); (b) for a drug other than trastuzumab—the distribution fee; (c) the dispensing fee; (d) the preparation fee; (e) the diluent fee. (2) The base price for a dose of a chemotherapy drug is the lowest sum of reference prices for a chemotherapy pharmaceutical benefit or combination of chemotherapy pharmaceutical benefits that make up an amount of the drug equal to or greater than the dose.
Note: If there is more than one chemotherapy pharmaceutical benefit or combination of chemotherapy pharmaceutical benefits that contains enough of the drug to make up the dose, the base price is determined by the lowest priced benefit or combination of benefits.
(3) A combination of chemotherapy pharmaceutical benefits includes a quantity of 2 or more of the same chemotherapy pharmaceutical benefit.
Note: Example: Two of the same chemotherapy pharmaceutical benefit, each of which contains 50 mg of a drug, could be used in combination to make up an amount of 100 mg of the drug. The reference price for each 50 mg would be added together to calculate the price of the combination.
(4) In this section, the reference price of a chemotherapy pharmaceutical benefit is the sum, rounded to the nearest cent (with a half cent being rounded up), of: (a) the single unit ex‑manufacturer price for the chemotherapy pharmaceutical benefit, rounded to the nearest cent (with a half cent being rounded up); and (b) 1.4% of the single unit ex‑manufacturer price for the chemotherapy pharmaceutical benefit.